Anti-Mouse PD-L1 (CD274) — Biotin - 50 µg

Quality Tested by Leinco Flow Cytometry: It is recommended to use the indirect method for signal enhancement when enumerating cells expressing B7-H1. A suggested method would be to stain cells expressing B7-H1 with 3 - 10 µg per 1 x 10⁶ cells in a total staining volume of 100 µl followed by PN:A104.
Western Blotting: To detect Mouse B7-H1 this biotin conjugate can be used at a concentration of 0.1 - 0.2 µg/ml. This biotin conjugate should be used in conjunction with compatible second-step reagents such as PN:A106 and a chromogenic substrate such as PN:T343. The detection limit for Mouse B7-H1 is 2 ng/lane under either reducing or non-reducing conditions. The sensitivity of detection may increase up to 50 fold when a chemiluminescent substrate is used.

PD-L1

Next Day Ambient

PD-1 is a 50-55 kD member of the B7 Ig superfamily. PD-1 is also a member of the extended CD28/CTLA-4 family of T cell regulators and is suspected to play a role in lymphocyte clonal selection and peripheral tolerance. The ligands of PD-1 are PD-L1 and PD-L2, and are also members of the B7 Ig superfamily. PD-1 and its ligands negatively regulate immune responses. PD-L1, or B7-Homolog 1, is a 40 kD type I transmembrane protein that has been reported to costimulate T cell growth and cytokine production. The interaction of PD-1 with its ligand PD-L1 is critical in the inhibition of T cell responses that include T cell proliferation and cytokine production. PD-L1 has increased expression in several cancers. Inhibition of the interaction between PD-1 and PD-L1 can serve as an immune checkpoint blockade by improving T-cell responses In vitro and mediating preclinical antitumor activity. Within the field of checkpoint inhibition, combination therapy using anti-PD1 in conjunction with anti-CTLA4 has significant therapeutic potential for tumor treatments. PD-L2 is a 25 kD type I transmembrane ligand of PD-1. Via PD-1, PD-L2 can serve as a coinhibitor of T cell functions. Regulation of T cell responses, including enhanced T cell proliferation and cytokine production, can result from mAbs that block the PD-L2 and PD-1 interaction.

PD-L1

AB_2828271

PD-L1 is present on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes.

Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.